JP6411523B2 - プリナブリン及びタキサンの組合せがん治療 - Google Patents
プリナブリン及びタキサンの組合せがん治療 Download PDFInfo
- Publication number
- JP6411523B2 JP6411523B2 JP2016547208A JP2016547208A JP6411523B2 JP 6411523 B2 JP6411523 B2 JP 6411523B2 JP 2016547208 A JP2016547208 A JP 2016547208A JP 2016547208 A JP2016547208 A JP 2016547208A JP 6411523 B2 JP6411523 B2 JP 6411523B2
- Authority
- JP
- Japan
- Prior art keywords
- docetaxel
- plinabulin
- tumor
- group
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2013/085075 WO2015051543A1 (en) | 2013-10-11 | 2013-10-11 | Cancer treatment with combination of plinabulin and taxane |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018179866A Division JP2018199726A (ja) | 2018-09-26 | 2018-09-26 | プリナブリン及びタキサンの組合せがん治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016536352A JP2016536352A (ja) | 2016-11-24 |
| JP2016536352A5 JP2016536352A5 (enExample) | 2017-01-05 |
| JP6411523B2 true JP6411523B2 (ja) | 2018-10-24 |
Family
ID=52812462
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016547208A Active JP6411523B2 (ja) | 2013-10-11 | 2013-10-11 | プリナブリン及びタキサンの組合せがん治療 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US10596169B2 (enExample) |
| EP (1) | EP3076972B1 (enExample) |
| JP (1) | JP6411523B2 (enExample) |
| KR (1) | KR102225371B1 (enExample) |
| CN (1) | CN105705148B (enExample) |
| AU (1) | AU2013402794B2 (enExample) |
| BR (1) | BR112016007946A2 (enExample) |
| CA (1) | CA2926771C (enExample) |
| DK (1) | DK3076972T3 (enExample) |
| ES (1) | ES2902665T3 (enExample) |
| IL (1) | IL244984B (enExample) |
| MX (1) | MX384751B (enExample) |
| MY (1) | MY185650A (enExample) |
| NZ (1) | NZ719049A (enExample) |
| RU (1) | RU2662298C2 (enExample) |
| SG (1) | SG11201602637QA (enExample) |
| WO (1) | WO2015051543A1 (enExample) |
| ZA (1) | ZA201602380B (enExample) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10357491B2 (en) | 2015-03-06 | 2019-07-23 | Beyondspring Pharmaceuticals, Inc. | Method of treating a brain tumor |
| US10668063B2 (en) | 2015-03-06 | 2020-06-02 | Beyondspring Pharmaceuticals, Inc. | Method of treating cancer associated with a RAS mutation |
| US11400086B2 (en) | 2017-02-01 | 2022-08-02 | Beyondspring Pharmaceuticals, Inc. | Method of reducing chemotherapy-induced neutropenia |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX394865B (es) * | 2015-02-12 | 2025-03-24 | Beyondspring Pharmaceuticals Inc | Uso de plinabulina en combinación con inhibidores de punto de control inmunitario |
| EP3334726B1 (en) * | 2015-07-13 | 2022-03-16 | Beyondspring Pharmaceuticals, Inc. | Plinabulin compositions |
| US10912748B2 (en) | 2016-02-08 | 2021-02-09 | Beyondspring Pharmaceuticals, Inc. | Compositions containing tucaresol or its analogs |
| CN109475524A (zh) | 2016-06-06 | 2019-03-15 | 万春药业公司 | 用于减少中性粒细胞减少症的组合物和方法 |
| WO2018129381A1 (en) | 2017-01-06 | 2018-07-12 | Beyondspring Pharmaceuticals, Inc. | Tubulin binding compounds and therapeutic use thereof |
| BR112019018880A2 (pt) * | 2017-03-13 | 2020-04-14 | Beyondspring Pharmaceuticals, Inc. | composições de plinabulina e seu uso |
| CN109498627B (zh) * | 2017-09-15 | 2021-06-04 | 深圳华大海洋科技有限公司 | 一种治疗肿瘤的药物组合物及其应用 |
| WO2019147615A1 (en) * | 2018-01-24 | 2019-08-01 | Beyondspring Pharmaceuticals, Inc. | Composition and method for reducing thrombocytopenia via the administration of plinabulin |
| BR112020015758A2 (pt) * | 2018-02-01 | 2020-12-08 | Beyondspring Pharmaceuticals, Inc. | Composição e método para reduzir neutropenia induzida por quimioterapia através da administração de plinabulina e agente de g-csf |
| CN108524442B (zh) * | 2018-06-05 | 2022-01-28 | 深圳海王医药科技研究院有限公司 | 一种抗肿瘤药物的注射剂及其制备方法 |
| JP2018199726A (ja) * | 2018-09-26 | 2018-12-20 | ビヨンドスプリング インコーポレイテッド | プリナブリン及びタキサンの組合せがん治療 |
| AU2019378779A1 (en) * | 2018-11-14 | 2021-06-03 | Beyondspring Pharmaceuticals, Inc. | Methods of treating cancer using tubulin binding agents |
| CN110507653B (zh) * | 2019-08-02 | 2022-12-02 | 北京赛而生物药业有限公司 | 多潘立酮及其与紫杉醇联用在制备治疗癌症的药物中的应用 |
| CN113613654B (zh) * | 2019-10-15 | 2024-01-26 | 大连万春布林医药有限公司 | 普那布林在制备增加非转移性乳腺癌患者触珠蛋白的药物中的用途 |
| EP4319751A4 (en) | 2021-04-09 | 2025-02-26 | Beyondspring Pharmaceuticals, Inc. | THERAPEUTIC COMPOSITIONS AND METHODS FOR THE TREATING OF TUMORS |
| CN113456643B (zh) * | 2021-08-11 | 2022-04-01 | 遵义医科大学 | 一种含普那布林的药物组合及其应用 |
| CN117860672A (zh) * | 2022-10-11 | 2024-04-12 | 大连万春布林医药有限公司 | 一种普那布林胶束组合物及其制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7141603B2 (en) | 1999-02-19 | 2006-11-28 | The Regents Of The University California | Antitumor agents |
| US7012100B1 (en) | 2002-06-04 | 2006-03-14 | Avolix Pharmaceuticals, Inc. | Cell migration inhibiting compositions and methods and compositions for treating cancer |
| AU2003302721B2 (en) | 2002-08-02 | 2009-10-08 | Beyondspring Pharmaceuticals, Inc. | Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof |
| US7919497B2 (en) | 2002-08-02 | 2011-04-05 | Nereus Pharmaceuticals, Inc. | Analogs of dehydrophenylahistins and their therapeutic use |
| BRPI0506655A (pt) * | 2004-02-04 | 2007-05-08 | Nereus Pharmaceuticals Inc | dehidrofenilahistinas e seus análogos, e sìntese de dehidrofenilahistinas e seus análogos |
| GB0907551D0 (en) * | 2009-05-01 | 2009-06-10 | Univ Dundee | Treatment or prophylaxis of proliferative conditions |
| CA2905418C (en) | 2013-03-13 | 2023-03-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods for modulating chemotherapeutic cytotoxicity |
-
2013
- 2013-10-11 EP EP13895342.7A patent/EP3076972B1/en active Active
- 2013-10-11 AU AU2013402794A patent/AU2013402794B2/en active Active
- 2013-10-11 NZ NZ719049A patent/NZ719049A/en unknown
- 2013-10-11 KR KR1020167012255A patent/KR102225371B1/ko active Active
- 2013-10-11 DK DK13895342.7T patent/DK3076972T3/da active
- 2013-10-11 SG SG11201602637QA patent/SG11201602637QA/en unknown
- 2013-10-11 WO PCT/CN2013/085075 patent/WO2015051543A1/en not_active Ceased
- 2013-10-11 MX MX2016004441A patent/MX384751B/es unknown
- 2013-10-11 BR BR112016007946A patent/BR112016007946A2/pt not_active Application Discontinuation
- 2013-10-11 RU RU2016112608A patent/RU2662298C2/ru active
- 2013-10-11 CA CA2926771A patent/CA2926771C/en active Active
- 2013-10-11 CN CN201380080185.5A patent/CN105705148B/zh active Active
- 2013-10-11 JP JP2016547208A patent/JP6411523B2/ja active Active
- 2013-10-11 MY MYPI2016000620A patent/MY185650A/en unknown
- 2013-10-11 US US15/028,376 patent/US10596169B2/en active Active
- 2013-10-11 ES ES13895342T patent/ES2902665T3/es active Active
-
2016
- 2016-04-07 IL IL244984A patent/IL244984B/en unknown
- 2016-04-08 ZA ZA2016/02380A patent/ZA201602380B/en unknown
-
2020
- 2020-03-17 US US16/821,348 patent/US20200281921A1/en not_active Abandoned
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10357491B2 (en) | 2015-03-06 | 2019-07-23 | Beyondspring Pharmaceuticals, Inc. | Method of treating a brain tumor |
| US10668063B2 (en) | 2015-03-06 | 2020-06-02 | Beyondspring Pharmaceuticals, Inc. | Method of treating cancer associated with a RAS mutation |
| US11400086B2 (en) | 2017-02-01 | 2022-08-02 | Beyondspring Pharmaceuticals, Inc. | Method of reducing chemotherapy-induced neutropenia |
Also Published As
| Publication number | Publication date |
|---|---|
| MX384751B (es) | 2025-03-14 |
| WO2015051543A1 (en) | 2015-04-16 |
| CA2926771C (en) | 2022-07-05 |
| EP3076972A4 (en) | 2017-12-20 |
| AU2013402794B2 (en) | 2020-02-27 |
| IL244984A0 (en) | 2016-05-31 |
| NZ719049A (en) | 2020-06-26 |
| KR20160078987A (ko) | 2016-07-05 |
| RU2662298C2 (ru) | 2018-07-25 |
| WO2015051543A8 (en) | 2016-04-21 |
| US20200281921A1 (en) | 2020-09-10 |
| EP3076972B1 (en) | 2021-10-06 |
| RU2016112608A (ru) | 2017-11-16 |
| AU2013402794A1 (en) | 2016-05-12 |
| ES2902665T3 (es) | 2022-03-29 |
| US20160250209A1 (en) | 2016-09-01 |
| CN105705148B (zh) | 2021-03-23 |
| MY185650A (en) | 2021-05-27 |
| SG11201602637QA (en) | 2016-05-30 |
| DK3076972T3 (da) | 2022-01-03 |
| KR102225371B1 (ko) | 2021-03-10 |
| US10596169B2 (en) | 2020-03-24 |
| CA2926771A1 (en) | 2015-04-16 |
| ZA201602380B (en) | 2022-05-25 |
| MX2016004441A (es) | 2016-10-28 |
| JP2016536352A (ja) | 2016-11-24 |
| IL244984B (en) | 2022-05-01 |
| BR112016007946A2 (pt) | 2017-09-12 |
| CN105705148A (zh) | 2016-06-22 |
| EP3076972A1 (en) | 2016-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016536352A (ja) | プリナブリン及びタキサンの組合せがん治療 | |
| EP3313433A1 (en) | Combination of hdac inhibitor and anti-pd-l1 antibody for treatment of cancer | |
| JP2012500180A5 (enExample) | ||
| JP2004531549A (ja) | Ｎ−｛５−［４−（４−メチル−ピペラジノ−メチル）−ベンゾイルアミド］−２−メチルフェニル｝−４−（３−ピリジル）−２−ピリミジン−アミンおよび化学療法剤を含んでなる併用剤 | |
| JP2022529295A (ja) | ユーイング肉腫治療用キノリン系化合物又はその薬学的に許容される塩 | |
| WO2016168451A1 (en) | Compositions for improving the pharmacokinetics and therapeutic index of cancer treatment | |
| ES2984487T3 (es) | Uso combinado de marizomib y bevacizumab para el tratamiento de cánceres del sistema nervioso central (SNC) | |
| US11000518B2 (en) | Use of combination of VEGFR inhibitor and PARP inhibitor in preparation of medicament for treating gastric cancer | |
| CN113939297A (zh) | 用于治疗Notch活化的乳腺癌的双氟烷基-1,4-苯并二氮杂卓酮化合物 | |
| JP2018199726A (ja) | プリナブリン及びタキサンの組合せがん治療 | |
| JP2021508699A (ja) | トリプルネガティブ乳がんを処置するためのｐｄ−１抗体及びアパチニブの併用処置の使用 | |
| HK1229712B (en) | Cancer treatment with combination of plinabulin and taxane | |
| US20230338347A1 (en) | New Use of Inhibitors of the Notch Signalling Pathway | |
| WO2018133838A1 (zh) | Egfr/her2抑制剂联合嘧啶类抗代谢药物的用途 | |
| TW202615103A (zh) | 一種抗體藥物偶聯物與酪胺酸激酶抑制劑的組合 | |
| CN115779095A (zh) | 治疗结直肠癌的喹啉衍生物与pd-1单抗的药物组合 | |
| JP2019513767A (ja) | マントル細胞リンパ腫の治療における使用のためのラムシルマブ及びアベマシクリブの組み合わせ療法 | |
| JP2025505381A (ja) | フタラジノン誘導体を含む抗癌剤との併用投与用薬学的組成物 | |
| AU2022233742A1 (en) | Use of oregovomab and bevacizumab, paclitaxel, carboplatin for treatment of brca-wild type platinum sensitive recurrent | |
| JP6643978B2 (ja) | 頭頚部がんの処置または予防において使用されるｐｉ３キナーゼ阻害剤とパクリタキセルの組合せ | |
| HK1261494A1 (en) | Use of combination of vegfr inhibitor and parp inhibitor in preparation of medicament for treating gastric cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20160613 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20160613 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160920 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161011 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20161011 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20170728 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170808 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20171107 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180109 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180208 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20180208 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180320 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180620 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180828 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180926 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6411523 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |